

Special Issue

Pharmacoepidemiology and Pharmacovigilance in the UK

Message from the Guest Editor

The UK has a long tradition of pharmacoepidemiology and pharmacovigilance; with a publicly funded system that provides universal health care, and electronic systems capturing a wide range of data, it is in a favourable position to conduct population-wide research in these areas. Considering developments such as an increasing population age, economic challenges, and public health threats such as the recent COVID-19 pandemic, obtaining an overview of current research and ongoing surveillance activities in the UK is warranted. For this Special Issue, authors are invited to submit original research and comprehensive reviews on all aspects related to pharmacoepidemiology and pharmacovigilance in the UK. This may include (but is not restricted to) manuscripts focusing on methodological developments; clinically relevant findings; clinical and/or cost-effectiveness; and the relevance of research and its impact on clinical practice. I look forward to receiving your contributions.

Guest Editor

Dr. Tanja Mueller

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK

Deadline for manuscript submissions

31 October 2025



Pharmacoepidemiology

an Open Access Journal
by MDPI

Indexed in Scopus
Tracked for Impact Factor



mdpi.com/si/208288

Pharmacoepidemiology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmacoepidemiology@mdpi.com

[mdpi.com/journal/
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)





Pharmacoepidemiology

an Open Access Journal
by MDPI

Indexed in Scopus
Tracked for Impact Factor



[mdpi.com/journal/
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)



About the Journal

Message from the Editor-in-Chief

We are very proud to launch this new, international, peer-reviewed, and open access journal. The main aim of *Pharmacoepidemiology* is to publish novel and up-to-date research findings, reviews, and communications on the beneficial effects of drugs as well as their potential adverse effects on humans through epidemiological studies conducted in the real world on large populations.

All researchers working in the pharmacoepidemiologic field—such as epidemiologists, clinical researchers, pharmacologists, clinicians, and biostatisticians—are welcome to contribute to *Pharmacoepidemiology*.

Editor-in-Chief

Dr. Carlotta Franchi

Laboratory of Pharmacoepidemiology and Human Nutrition,
Department of Health Policy, Istituto di Ricerche Farmacologiche Mario
Negri IRCCS, Milan, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.6 days after submission; acceptance to publication is undertaken in 3.2 days (median values for papers published in this journal in the first half of 2025).